Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens, Maiwenn Al

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
16 Downloads (Pure)
Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalPharmacoeconomics (Online)
Volume34
Issue number1
DOIs
Publication statusPublished - 2016

Research programs

  • EMC NIHES-05-63-02 Quality

Cite this